

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Ranibizumab and pegaptanib for the treatment of Age-related macular degeneration (AMD)

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals Ltd (ranibizumab) • Pfizer Ltd (pegaptanib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Blind People • Age Concern England • Association of Blind Asians (ABA) • British Association for Service to the Elderly • Counsel and Care for the Elderly • Eyecare Trust • Fight for Sight • Help the Aged • Macular Disease Society • Royal National Institute of the Blind • Seeability (operating name of the Royal School for the Blind) • Sense • Specific Eye Conditions (SPECS) • Thomas Pocklington Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Geriatrics Society • College of Optometrists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists • Royal College of Physicians of Edinburgh • Royal Pharmaceutical Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health 	<p><u>General</u></p> <ul style="list-style-type: none"> • British National Formulary • Medicines and Healthcare products Regulatory Agency (MHRA) • NHS Confederation • NHS Purchasing and Supplies Agency • NHS Quality Improvement Scotland <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Novartis Ophthalmics (Verteporfin/PDT) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Institute of Ophthalmology, University College London <p><u>Assessment team</u></p> <ul style="list-style-type: none"> • National Coordinating Centre for Health Technology Assessment • Southampton Health Technology Assessment Centre (SHTAC) <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre Acute Care

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none">• Heywood and Middleton PCT• High Peak and Dales PCT• Welsh Assembly Government	

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).